Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGER1 | P34995 | 7/20 | 0.48 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | MAP3K5 | Q99683 | 7/20 | 0.40 |
| ▸ | JAK2 | O60674 | 1/20 | 0.40 |
| ▸ | JAK3 | P52333 | 1/20 | 0.40 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.40 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.40 |
| ▸ | UCHL1 | P09936 | 1/20 | 0.39 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.38 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3180343 | 0.91 | PTGER1 (0.50) | PTGER1ESR2CYP2C9MAP3K5NR1H2 | |
| SCHEMBL3179360 | 0.90 | PTGER1 (0.49) | PTGER1ESR2CYP2C9MAP3K5NR1H2 | |
| SCHEMBL3186031 | 0.89 | PTGER1 (0.52) | PTGER1ESR2CYP2C9MAP3K5NR1H2 | |
| SCHEMBL3587201 | 0.88 | PTGER1 (0.50) | PTGER1ESR2CYP2C9MAP3K5JAK2 | |
| SCHEMBL3186073 | 0.88 | PTGER1 (0.45) | PTGER1ESR2CYP2C9MAP3K5NR1H2 | |
| SCHEMBL3581181 | 0.86 | PTGER1 (0.48) | PTGER1ESR2CYP2C9MAP3K5JAK2 | |
| SCHEMBL3176471 | 0.84 | PTGER1 (0.55) | PTGER1ESR2CYP2C9 | |
| SCHEMBL3176691 | 0.84 | PTGER1 (0.57) | PTGER1ESR2CYP2C9 | |
| SCHEMBL3186899 | 0.82 | PTGER1 (0.52) | PTGER1ESR2CYP2C9MAP3K5 | |
| SCHEMBL3582433 | 0.82 | PTGER1 (0.63) | PTGER1CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100022486-A1 | COMPOUNDS | SMITHKLINE BEECHAM CORPORATION | 2010-01-28 | — | — | US | disclosed |
| US-20100022486-A1 | COMPOUNDS | SMITHKLINE BEECHAM CORPORATION | 2010-01-28 | — | — | US | disclosed |
| US-20100022486-A1 | COMPOUNDS | SMITHKLINE BEECHAM CORPORATION | 2010-01-28 | — | — | US | disclosed |
| WO-2008074832-A2 | ISOQUINOLINECARBOXAMIDES AS INHIBITORS OF STEAROYL-COA DESATURASE ( SCD) | SMITHKLINE BEECHAM CORPORATION (US) | 2008-06-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100022486-A1 | COMPOUNDS | SCD, CYP11B2, SCD5 | PTGER1 681/4885ESR2 2943/4885CYP2C9 34/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.